Narine Vartanian

Dr. Narine Vartanian


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
NVNarine Vartanian
Narine Vartanian
SBSophia Bishop
Sophia Bishop
JTJoseph Tang
Joseph Tang
KCKyle Cuneo
Kyle Cuneo
DCDaniel T Chang
Daniel T Chang
AEAmeer L. Elaimy
Ameer L. Elaimy
The therapeutic landscape of hepatocellular carcinoma (HCC) has evolved with advances in systemic therapy and radiotherapy. Immune-checkpoint inhibitors, anti-angiogenic agents, stereotactic body radiotherapy (SBRT), and yttrium-90 transarterial radioembolization (TARE) have expanded treatment options across multiple stages of disease. Radiotherapy may complement systemic therapy through biological interactions involving tumor vasculature, hypoxia, and the immune microenvironment. These observations have generated growing interest in combined-modality therapy, although optimal approaches continue to be defined. In this review, we summarize the biological rationale and clinical evidence for integrating SBRT or TARE with targeted and immunotherapy-based regimens. We also highlight ongoing trials and emerging strategies for biologically informed therapy sensitization targeting tumor and immune-cell biology.